Rainbow æäººã¹ã¯ãªãŒãã³ã°ã®ããã®ãšããœãŒã ã·ãŒã±ã³ã·ã³ã°æ€æ»
ã¯ããã«
5,000以äžãã®éºäŒåçŸæ£ãç¥ãããŠããŸããããã«ã6,000以äžãã®å¥åº·ç¶æ ãå«ãå€ãã®å ±åãæ§ã ãªèšåºããã³ãã€ãªã€ã³ãã©ããã£ã¯ã¹ã»ããŒã¿ããŒã¹ã«èç©ãããŠããŸããèšåºå šãšã¯ãœãŒã ã·ãŒã±ã³ã·ã³ã°ã§ã¯22,000ãã®éºäŒåã察象ãšããããšã§ããããçŸæ£ã«é¢ä¿ããç åæ§å€ç°ã«å¯ŸããŠç¶²çŸ çã«ã¹ã¯ãªãŒãã³ã°ãè¡ããŸãã
å€ãã®æ¶è²»è çŽè²©åã®éºäŒåæ€æ»ã§ã¯ãèšåºäžã®æçšæ§ããªãç¥èŠã倿°ãããŸããRainbowãæäŸããå šãšã¯ãœãŒã ã·ãŒã±ã³ã·ã³ã°æ€æ»ã¯ããã®ãããªãã¬ã¯ãªãšãŒã·ã§ã³çãªéºäŒåæ€æ»ããšã¯ç°ãªããæçãªå»åŠçæ ¹æ ããã³ãèšåºçã«å¯Ÿå¿å¯èœãªç åæ§ã®ããåã¯ãç åæ§ã®ããå¯èœæ§ã®é«ãå€ç°ãå ±åããŸããã€ãŸããæ€æ»çµæãåºã«ãããªãã®äž»æ²»å»ã¯çŸæ£ãžã®ãªã¹ã¯ã«åããã¹ã¯ãªãŒãã³ã°ããã³ãäºé²å¯Ÿçãè¬ããããšãå¯èœãšãªããŸãããŸããåœç€Ÿã®éºäŒåã«ãŠã³ã»ã©ãŒããå©çšé ãããšã§ãããèªèº«ã®å¥åº·ç¶æ ããã³å¿çç¶æ ã«å¯Ÿããçè§£ãæ·±ããçžè«ããããå¯èœã§ãã
Rainbow æäººã¹ã¯ãªãŒãã³ã°ã®ããã®ãšããœãŒã ã·ãŒã±ã³ã·ã³ã°æ€æ»
Rainbow Adult Screening Exome Sequencing Testã§ã¯èšåºçã«å¯Ÿå¿å¯èœãªæ¬¡ã®çµæãæäŸããŸãïŒ
ããªãã®å¥åº· â ããªããå°æ¥ãçºçãããéºäŒåçŸæ£ã®ãªã¹ã¯ã«ã€ããŠ
ããªãã®ãªãããã¯ãã£ãã»ãã«ã¹ ïŒ ããªãã®éºäŒåã®åé¡ãããªãã®ã忝ãžåãæž¡ããªã¹ã¯ã«ã€ããŠ
340以äžã®å»è¬åã«å¯Ÿããåå¿ã«ã€ããŠ
å¿çæ¢å¡ãããã³èè¡æ§è³åäžã«å¯Ÿãããªã¹ã¯ã«ã€ããŠ
ããªãã ãã®ã1æéã®ç¡æãã€ãªã³ã¬ã«âéºäŒåã«ãŠã³ã»ãªã³ã°ã»ã»ãã·ã§ã³âãå«ã¿ãŸãïŒ
èšåºçã«å¯Ÿå¿å¯èœãªçµæãæäŸããããšã§ãããªãã®äž»æ²»å»ã¯ããªãã«åã£ãäºé²å¯Ÿçãåããããªãã«åã£ãã±ã¢ãããããšãã§ããŸãã
æ€æ»å 容
ããªãã®å¥åº·
22,000ãã®éºäŒåãå šãšã¯ãœãŒã ããæ€æ»ããããšã§ãããªããçºçãããéºäŒåçŸæ£ã®ãªã¹ã¯ã調ã¹ãŸããçŸæ£ã«ã¯ããããå¿çŸæ£ãç¥çµé害ãããŠãä»ã®ã¡ã³ãã«éºäŒç ãåäžéºäŒåçŸæ£ãªã©å€ããå«ãŸããŸãã
çŸåšã5,000ãã®éºäŒåçŸæ£ã確èªãããŠãããã»ãšãã©ãåžå°çŸæ£ã§ããããããªãããå¿çŸæ£ãããããªã©ã®äžã«ããéºäŒåãšå¯æ¥ãªé¢ä¿ãæ€èšŒãããŠãããã®ããããŸããäŸãšããŠãä¹³ãããå€§è žããã®å 5%ã¯éºäŒåã«èµ·å ããããšã確èªãããŠããŸãããŸãã500人ã«1人ã¯å¿ççã«é¢ããéºäŒåå€ç°ãæã€ããšã確èªãããŠããŸãã
ãã®æ€æ»ã§ã¯ãéºäŒåçŸæ£ãšé¢é£ããç åæ§ã®ããããŸãã¯ç åæ§ã®ããå¯èœæ§ã®é«ãå€ç°ã«å¯ŸããŠæž¬å®ãè¡ããŸãããŸãããããã¯ç§åŠçãªåŠè¡è«æã«ãŠå ±åãããŠãããçŸæ£çºçãªã¹ã¯ã®äžæãšã®å ææ§ããããšèããããå€ç°ã§ãã
ç åæ§éºäŒåå€ç°ããã£ãŠããŠãå¿ ãããçŸæ£ã®çºçãžãšç¹ããããã§ã¯ãããŸãããæ€æ»ã«ãŠéœæ§çµæã衚ããå Žåãããªãã®äž»æ²»å»ã¯çŸæ£çºçãªã¹ã¯ã«å¯Ÿãäºé²å¯Ÿçãè¬ããããšãå¯èœãšãªãã§ãããã
ããªãã®ãªãããã¯ãã£ãã»ãã«ã¹
ãã®æ€æ»ã¯ããã£ãªã¢ã»ãã¹ãïŒä¿å è æ€æ»ïŒã«é¡äŒŒããŠããŸãã22,000ãã®éºäŒåã«å¯ŸããŠã¹ã¯ãªãŒãã³ã°ãè¡ããããªããã忝ãžåãç¶ããªã¹ã¯ãããã壿§éºäŒåçŸæ£ã«é¢é£ããç åæ§éºäŒåã®æž¬å®ãè¡ããŸãã
ãã£ãªã¢ã¹ã¯ãªãŒãã³ã°ã§ã¯ãããªãã®åã«é床ãªéºäŒåçŸæ£ãåŒãèµ·ããããéºäŒåå€ç°ããã€ãã©ããã確èªããŸããçŸåšã§ã¯1,300ãã®ãã£ãªã¢ãšãªãããéºäŒåã確èªãããŠããŸãããããã®å¥åº·ç¶æ ã¯åžå°ã§ãã»ãšãã©ãäžè¬çãªåºç忀æ»ã§èŠã€ããããšãäžå¯èœãšãããŠããŸãã
ãããã®çŸæ£ã¯å£æ§éºäŒã®ãããåãçºçããã«ã¯å€ç°ãäž¡èŠªåæ¹ããåãç¶ãããããšãæ¡ä»¶ãšãªããŸããäž¡èŠªåæ¹ããã£ãªã¢ã®å Žåãåããã®çŸæ£ãæ£ãå¯èœæ§ã¯1/4ã§ãã
æ¬§ç±³äŒæ¥ã«ãã£ãŠéçºãããŠããå€ãã®éºäŒåããã«ãã¹ãïŒ1-200çšåºŠã®éºäŒåãå«ãïŒã¯ãäž»ã«çœäººæ£è ã®ããŒã¿ã«åºã¥ããŠãããã¢ãžã¢äººã®éºäŒåã«é¢ããŠååã«ã¯ãããŸãããããããAdult Screening Exome Sequencing testã§ã¯ã22,000以äžã®éºäŒåããšã¯ãœãŒã ããæž¬å®ããŸããããã«ãã£ãŠæã ã¯ãã¢ãžã¢äººæ£è ã®ã¿ã«å¯æ¥ã«é¢ä¿ããéºäŒåã®æž¬å®ãæŒãããªã¹ã¯ãå€§å¹ ã«åæžããŠããŸãã
ãçæããã ãããç¹ïŒæ¬æ€æ»ã§ã¯ã以äžã®çŸæ£ã»éºäŒåã®ä¿å è æ€æ»ã¯è¡ããŸãããFragile Xã è髿§çèçž®çïŒSMNïŒã ãµã©ã»ã㢠(HBA)
ããªãã®340以äžã®å»è¬åã«å¯Ÿããè¬å€åå¿ã«ã€ããŠ
Rainbow Genomicsã¯OneOme 瀟ïŒç±³åœãããœã¿å·ããã¢ããªã¹ïŒãšå ±ã«ãç¶²çŸ çã§èšåºçã«å¯Ÿå¿å¯èœãªãã¡ãŒãã³ã²ããã¯ã¹æ€æ»ãæ£è ããã³å»åž«ã«æäŸããŠããŸããOneOme RightMedãã¡ãŒãã³ã²ããã¯ã¹æ€æ»ã
ãŸããOneOme瀟ã¯ãMayo ClinicïŒç±³åœãããœã¿å·ããã§ã¹ã¿ïŒãšã®å ±åéçºããã³ç¬å ã©ã€ã»ã³ã¹å¥çŽãçµãã§ããŸãããã®ãããæ£è ã®éºäŒåãã©ã®ããã«340以äžã®è¬å€ã«åå¿ããã®ããç¶²çŸ çã«ç¥ãããšãå¯èœã§ããOneOme瀟ã§ã¯æ£è ã®éºäŒåæ å ±ãè§£æããããšã§ãèšåºçã«è£ä»ãã®ããã¬ããŒããå»åž«ããã³æ£è ãžæäŸãå¯èœã§ãã
粟確æ§ã«æ¬ ããåŠæ¹ã¯å¹æçãªæ²»çãé å»¶ãããã ãã§ãªããåå ¥é¢ãæå®³äºè±¡ãèµ·ããããŸãèŽæ»çããäžããŸããè¿å¹Žã®ç±³åœã®èª¿æ»ã§ã¯ãåŠæ¹è¬ã®å€ãã¯50-75%ã®æ£è ã®ã¿ã«ãã广ã瀺ããªãããšã倿ããŠããŸãããŸããç±³åœã§ã¯åŠæ¹è¬ã®å¯äœçšãæ»äº¡èŠå ã®ç¬¬4äœãšãããŠããŸããæ¬æ€æ»ã§ã¯ãå»è¬åå¯äœçšãäœæžãããåŠæ¹è¬ã®å¹èœãäžæãããæå³ããªãå»è¬åéã®åå¿ãé¿ããããšãç®çãšããŠããŸãã
ç¶²çŸ çïŒ22éºäŒåã340以äžã®äžè¬åŠæ¹è¬ãããã³28ã®å¥åº·ç¶æ
ä¿¡é Œæ§ïŒã¢ã¡ãªã«é£åå»è¬åå±ã©ãã«æ å ±ãèšåºè¬çéºäŒåŠå±¥è¡åäŒïŒClinical Pharmacogenetics Implementation ConsortiumïŒãä»ã®å°éã¬ã€ãã©ã€ã³ããã³åŠè¡ç ç©¶ãªã©èšåºç¢ºèªãåãããã®ã®äžããMayo Clinic瀟ãšå ±ã«ããã«ç²Ÿéžãããèšåºãšããã³ã¹ã掻çšããŠããŸãã
ããªãã®çç¶ã«å¯ŸããéºäŒåæ€æ»
5,000以äžãã®ãã¡ã³ãã«éºäŒç ãåäžéºäŒåçŸæ£ãç¥ãããŠããŸããå®¶ææŽããéºäŒçèŠå ã«åºã¥ããããããªãçç¶ããããçŸåšãæã¡ã§ããã°ãããªãã®äž»æ²»å»ã¯æ€æ»æ³šææã«çç¶ã«é¢ããæ å ±ãåŒç€Ÿãžãç¥ããããã ãããšãã§ããŸãã
Baylor Genetics瀟ã§ã¯ãããªãã®çç¶ãéºäŒçèŠå ã«åºã¥ããã®ãã©ãããåæããŒã¿ãšèšåºè§£éããæ€èšããŸãããã®åæã§ã¯ãç åæ§ã®ããããŸãã¯ç åæ§ã®ããå¯èœæ§ã®é«ãå€ç°ã¯ãã¡ããã®ããšãªãããä»ã®èšåºçæçŸ©ã®äžç¢ºå®ãªå€ç°ãæ€æ»ãããŸãã
çµæã¯å»åž«ã®ã¬ããŒãã®äžéšãšããŠãBaylor Genetics瀟ã®ç±³åœã®åœå®¶è³æ Œãæã€äž»ä»»å»åž«ããçºè¡ãããŸãããŸããç±³åœã®åœå®¶è³æ Œãæã€éºäŒã«ãŠã³ã»ã©ãŒã«ãããã€ãªã³ã¬ã«ã®éºäŒã«ãŠã³ã»ãªã³ã°ãæäŸãããŸããåæã«å»åž«ã«ããã³ã³ãµã«ãã£ã³ã°ãè¡ãããŸãããããã®ç±³åœã®åœå®¶è³æ Œãæã€èªå®å°éå»ãã«ããé¢è«ã¯ãã©ã€ãã®ãã¬ãäŒè«ã«ãã£ãŠæäŸãããŸãã
ããªãã®å¿çæ¢å¡ãããã³èè¡æ§è³åäžã®ãªã¹ã¯
å¿çæ¢å¡ïŒå¿èçºäœïŒãå¿çæ¢å¡ã¯ãå¿èãžã®è¡ã®æµããå¡ãããããšã§èµ·ããŸãããã£ãšãå€ãã®ã¯ãè質ãã³ã¬ã¹ãããŒã«ããä»ã®ç©è³ªã®å åèãžã®èç©ã«èµ·å ããŸããè¡æµã®åŠšå®³ã¯å¿çãžã®æå·ãäžããŸããå¿çæ¢å¡ãã€ãŸãå¿èçºäœïŒMIïŒã¯èŽæ»çã§ãã
å¿çæ¢å¡ã®ãªã¹ã¯èŠå ã«ã¯ãç°å¢å åãšéºäŒçå åã®äž¡æ¹ãååšããŸããMI Risk Assessment Testã§ã¯ãæè²äœ9p21ã«ååšãã2ã€ã®ãªã¹ã¯ããŒã«ãŒã®éºäŒååã調ã¹ãŸãããã®2ã€ã®äžå¡©åºéºäŒåå€åïŒSNPïŒã¯ãMIãããã³å åèå¿çŸæ£ã®çºçãªã¹ã¯ã®äžæã«å¯äžããŸãããªã¹ã¯ã®å¯äžã¯ã20,000åã®å¿çæ¢å¡æ£è ãš40,000åã®å¥åžžè ãããªã20ã®äººçš®ïŒ5,000åã®äžåœäººãæ¥æ¬äººãéåœäººããã³ä»ã®æ±ã¢ãžã¢äººãå«ãïŒã§ç¢ºèªãããŠããŸãã
å¿æ¿çްåïŒèè¡æ§è³åäžïŒãšã¯äžæŽããã€äž»ã«æ©ãå¿æçïŒäžæŽèïŒã§ãããçºäœãå¿äžå šãä»ã®å¿èã«é¢ããå䜵çã®ãªã¹ã¯ãäžæãããŸããå¿æ¿çްåã®ç¹°ãè¿ãã¯å¿æ¿ã§ã®è¡æ ã®åœ¢æã«ç¹ãããä»ã®èåšãžã®è¡ç®¡ã®è©°ãŸãïŒè¡æµäžå šïŒãšãªããŸãã
11幎ã®éãäžåœäººã®471,446åã察象ã«ããç ç©¶ã«ãããšãå¿æ¿çްåïŒAFïŒã¯20åã«èšãäžãã£ãŠããŸããäžåœäººã®ãçæ¶¯å¿æ¿çްåçºçãªã¹ã¯ã¯5人ã«1人ã§ãããAF Risk Assessment Testã§ã¯ãæè²äœ4q25ã«ãã転åå¶åŸ¡å åPITX2ä»è¿ã«ååšãã2ã€ã®ãªã¹ã¯ããŒã«ãŒãæ€èšããŸãã
10,000å以äžã®æ£è ãš30,000åã®å¥åžžè ãåºã«ããæ°ã ã®ç ç©¶ããã4q25ã«ãããªã¹ã¯ã¯çœäººãæ¥æ¬äººãäžåœäººãéåœäººã®äººçš®ã§ç¢ºèªãããŠããŸãã
èšåºè§£éã«é¢ããŠã¯ãæ¥æ¬ã®Rainbowã®èšåºããŒã ã«ãã£ãŠæäŸãããŸãã
ããªãã®éºäŒåã«ãŠã³ã»ãªã³ã°ã»ã»ãã·ã§ã³
æ£è ãžã®éºäŒåã«ãŠã³ã»ãªã³ã°ã
Rainbow Genomicsã§ã¯ã忀è ã«å¯Ÿããæ§ã ãªãã€ãªã³ã¬ã«éºäŒã«ãŠã³ã»ãªã³ã°ããå京èªãåºæ±èªãæ¥æ¬èªããããŠè±èªã§è¡ã£ãŠããŸããæ€æ»ã«ã¯ãã«ãŠã³ã»ãªã³ã°ãå«ãŸããŠãããå忀è ã«å¯ŸãBaylorå»ç§å€§åŠConsultageneã«ãããé»åã¡ãŒã«ãé»è©±ããã¬ãäŒè°ããŒã¹ã®éºäŒã«ãŠã³ã»ãªã³ã°ãè¡ãããŸãã忀è ãžã®è³ªã®é«ãã广çãªãµããŒãã®ãµãŒãã¹ããBaylorå»ç§å€§åŠã®ç±³åœã®åœå®¶è³æ Œãæã€éºäŒåã«ãŠã³ã»ã©ãŒã«ãã£ãŠæäŸãããŸãã
å»åž«ãžã®ã³ã³ãµã«ãã£ã³ã°ïŒ
ãã¢ããŒãã¢ã»ãã£ã¹ã«ãã·ã§ã³ãRainbow Genomicsã§ã¯ãçºæ³šããå»åž«ã®èœåã匷åãã忀è ã«å¯Ÿãæè¯ã®ã±ã¢ãã§ããããã«ã2ã€ã®ã¬ãã«ã§ãµããŒããè¡ããŸããå»åž«ã«å¯Ÿããé»åã¡ãŒã«ã«ããã³ã³ãµã«ãã£ã³ã°ãBaylor Genetics瀟ã®èªå®éºäŒåã«ãŠã³ã»ã©ãŒã«ãã£ãŠæäŸãããŸãã忀è ã®ã±ã¢ã«ã€ããŠãããæ·±ããã£ã¹ã«ãã·ã§ã³ãåžæããå»åž«ã«å¯ŸããŠã¯ãBaylorå»ç§å€§åŠã®Consultageneã«ãã£ãŠãBaylorå»ç§å€§åŠã®å»åž«ããçŽæ¥ã1æéã®ãã¬ãäŒè«ã«ãã£ãŠããã¢ããŒãã¢ã»ã³ã³ãµã«ãã£ã³ã°ãæäŸãããŸããäŒè«ã«ã¯ãçºæ³šããå»åž«ããã®ååè ãããã³å»çæäŸè ã®æ¹ã ã®åå ãæè¿ããããŸãã
ããã¿
ãã®ããã»ã¹ã¯ãå»åž«ã«ããRainbowèªå®ã¯ãªããã¯ã«èšªããŠãå»åž«ã®èšºå¯ãåããããšã«ããå§ãŸããŸãã忀è ã®ããã®æ€æ»ã®çºæ³šã¯ãã¯ãªããã¯ãè¡ããŸãã
ããªãã®DNAãµã³ãã«ã®ã·ãŒã±ã³ã·ã³ã°ã¯CAPïŒCollege of AmericanPathologistsïŒç±³åœç çåŠäŒïŒèªèšŒãŸãã¯ãCLIAïŒClinical Laboratory Improvement AmendmentïŒèšåºæ€æ»æ¹åä¿®æ£æ³æ¡ïŒèªå®ç ç©¶æã«ãŠè¡ãããŸããããŒã¿ã¯ACMGã¬ã€ãã©ã€ã³ã«åºã¥ããBaylor Genetics瀟ã«ãŠè§£æãããèšåºçãªè§£éãå ããããŸããå ããŠãå»åž«ã¬ããŒããBaylor Genetics瀟èªå®äž»ä»»å»åž«ã«ãã£ãŠçºè¡ãããŸãã
æ¥èšºæã«ããªãã®DNAãµã³ãã«æ¡åã¯ãå»åž«ãOneOme RightMed®ãã¡ãŒãã³ã²ããã¯ã¹æ€æ»ã®ç¶¿æ£ã§ãå£å ãè»œãæŠããé ¬ã¹ã¯ããã«ãã£ãŠè¡ãããŸãããµã³ãã«ã¯ãOneOme瀟ã®CAPèªèšŒãããã«CLIAèªå®ãããèšåºæ€æ»ã©ãã«éãããŸããæ€æ»ãè§£æãèšåºæ€æ»çµæã®çºè¡ã¯ãOneOme瀟ã®èšåºããŒã ã«ãã£ãŠè¡ãããŸãã
ãã®éºäŒåæ€æ»ãé©ããŠããæ¹
ä»®ã«ããªããéºäŒåå€ç°ãä¿æããŠãããããŸãã¯å®¶ç³»ã«ãã®ãããªå€ç°ãååšããŠããå¿ ãéºäŒåçŸæ£ãçºçããããã§ã¯ãããŸãããèªå®éºäŒåã«ãŠã³ã»ã©ãŒã«ããã«ãŠã³ã»ãªã³ã°ã¯ãããªãããã€ç¹å®ã®éºäŒåå€ç°ã®æå³ãçè§£ããããã«ããšãŠãéèŠã§ãã
ãããäžèšãåœãŠã¯ãŸãã®ã§ããã°ãRainbow Adult Screening Exome Sequencing testã¯ããªãã«ãšã£ãŠæé©ãããããŸããã
çŸåšå¥åº·ã§ãããèªåãå°æ¥çºçããå¯èœæ§ã®ãããéºäŒçãªãããå¿çŸæ£ãªã©ã®éºäŒåçŸæ£ã®çè§£ããããã
åäŸãå²ããäºå®ããããåäŸãžéºäŒåçŸæ£ãåãç¶ããªã¹ã¯ãç¥ãããã
340以äžã®å»è¬åã«å¯Ÿããåå¿ãç¥ãããã
ãããäžèšãåœãŠã¯ãŸãã®ã§ããã°ãããªãã«ãšã£ãŠæé©ã§ã¯ãªããããããŸããã
æ¢ã«é節ãªçç¶ãåºãŠãããéºäŒçãªèŠå ãæ€èšãããã
äŸãšããŠãããªããæ¢ã«ãããšèšºæãããŠããå Žåãããã®åå ç©¶æãããªãã¡å®¶ææ§ã®ãããã©ããããããªããšäž»æ²»å»ãç¥ãããå Žåããã®éã¯ãRainbow High-Risk Cancer testãæçšã§ãããã
ããªããšäž»æ²»å»ã培åºçã«è¡ãããéºäŒåæ€æ»ãæ¢ããŠããã
äŸãšããŠãããªãã®ãåæ§ãé²è¡æ§çãžã¹ãããã£ãŒãæ£ã£ãŠããã䞻治å»ãéºäŒåèŠå ã®æ€èšãè¡ãããå Žåããã®éã¯ãRainbow Pediatric Care testãæçšã§ããããæ€æ»ã§ã¯ããåæ§ã®ãšã¯ãœãŒã å ã®å š22,000 éºäŒåãããåå éºäŒåã®æ€èšãå¯èœã§ãããã